UW Researchers Use AI to Speed Up Drug Discovery

We're excited to spotlight Gene Williams, PhD, Vice President, Clinical Pharmacology. With more than 25 years of industry experience, including serving as a Team Leader and Primary Reviewer at the FDA, Dr. Williams brings a depth of expertise in clinical pharmacology and regulatory science to Allucent's A-Team. Dr. Williams and our Clinical Pharmacology experts partner with sponsors across drug development, applying clinical pharmacology, model-informed drug development (MIDD), and quantitative approaches to inform dose selection, study design, and other critical development decisions. By integrating scientific expertise with advanced modeling and analysis, our team helps sponsors reduce uncertainty and move programs forward with greater confidence. Learn how our Clinical Pharmacology team can support your next program: https://lnkd.in/gqEHZbfz #Allucent #BringingNewTherapiesToLight #ATeam #ClinicalPharmacology #ModelInformedDrugDevelopment #MIDD #SpecialtyCRO

IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026: Artificial Intelligence is rapidly transforming drug discovery, clinical research, and Alzheimer’s disease development, and IGC Pharma, Inc. (NYSE: IGC) is positioning itself at the forefront of that evolution. The clinical-stage biotechnology company will present seven scientific papers at the Alzheimer’s … Continue reading → #Business #Finance #FinancialMarket #PharmaceuticalsBiotech

Incredibly proud of our safety team for creating this brochure, so much labor went into it!!🥳 It is a FANTASTIC read for anyone interested in learning more about pre-clinical safety assessments, and we’ve even included a few related case studies at the end of the document. Click the link in the post to download the free PDF

Late-stage safety findings can derail promising drug candidates. Download De-Risking Drug Candidates Through Modernized In Vitro Safety Pharmacology to learn how today's approaches to secondary pharmacology can help identify risks earlier and improve decision-making across discovery programs. Inside: ✔️ Strategies for aligning safety screening with project goals ✔️ A clear overview of the latest 2024 recommendations for expanded target coverage ✔️ How AI-driven visualization tools can turn complex data into actionable insights Download the guide: https://lnkd.in/dBS9jhZK #DrugDiscovery #SafetyPharmacology #SAFETYscan #SafetyScreen #EurofinsDiscovery

Pharmacology Research: From Molecules to Medicines Every breakthrough in medicine begins with a well-designed research question. Pharmacology is not just about studying drugs; it's about understanding their mechanisms, improving patient outcomes, and driving innovations that shape the future of healthcare. I created this infographic as a quick reference for research scholars, postgraduate students, and early-career researchers. It summarizes the essential pillars of pharmacology research, including: ✔️ Drug Discovery & Development ✔️ Pharmacodynamics & Pharmacokinetics ✔️ Toxicology & Clinical Pharmacology ✔️ Computational Pharmacology & AI in Drug Discovery ✔️ Emerging Research Trends ✔️ Essential Research Tools & Resources Whether you're starting your first research project or advancing your Ph.D. journey, I hope this serves as a practical guide and a reminder that quality research begins with curiosity, scientific integrity, and continuous learning. What area of pharmacology research do you find most exciting in 2026? Share your thoughts in the comments—I’d love to hear your perspective.

Are you making Go/No-Go decisions based on the right data? In small molecule drug discovery, it is surprisingly common to see promising programs advance on the basis of encouraging early results, only to encounter major setbacks later in preclinical development. By then, significant time, effort, and millions of dollars may already have been invested. Before committing to the next stage of development, it is worth asking a few critical questions: ✔ Does the in vivo efficacy truly support the hypothesis? Statistical significance alone is not always sufficient. The biological relevance of the effect size, tumour growth kinetics, and absolute xenograft volumes should all be considered. For example, very small tumour volumes at study termination may warrant careful interpretation, even when p < 0.05. ✔ Is the exposure adequate? Without convincing pharmacokinetics and bioavailability, even an active compound may never achieve therapeutically relevant concentrations in patients. ✔ Do we have evidence of target engagement? Demonstrating that the compound reaches and modulates the intended target in the relevant biological context substantially strengthens confidence in the mechanism of action. ✔ How selective is the molecule? Understanding the secondary target profile early can help anticipate efficacy limitations, unexpected pharmacology, and potential safety concerns. ✔ Have the right safety liabilities been investigated? Early in vitro profiling (including hERG and other relevant assays) should be performed at pharmacologically meaningful concentrations. Testing only at very low concentrations may overlook liabilities that become apparent at clinically relevant exposures. Many of these aspects are acknowledged in principle, yet under the pressure to move programs forward they are sometimes underestimated or insufficiently integrated into decision-making. A rigorous, independent review of the available data before advancing a lead compound can prevent costly late-stage failures and help focus resources on molecules with the highest probability of success. At DTI-Tech, our consultants bring more than 50 years of combined experience in oncology, small molecule drug discovery, and preclinical development. We provide independent scientific due diligence on your lead compounds, critically reviewing efficacy, pharmacokinetics, target engagement, selectivity, safety data, and overall developability to help answer one fundamental question: Should this molecule move forward—and if so, what should be the next experiments? Sometimes, the most valuable experiment is knowing whether you need to perform the next one at all. #DrugDiscovery #PreclinicalDevelopment #Oncology #SmallMolecules #DrugDevelopment #TranslationalResearch #Biotech #Pharmacology #MedicinalChemistry #DTITech

Patent activity is the earliest quantitative signal of where drug discovery is heading — years before clinical programs go public. My colleagues at CAS and I analyzed 368,000+ global pharma patents (2020–2025), and the dominant trend is systematic expansion — into new modalities, new target classes, and disease areas that weren't previously considered tractable. 📍 Therapeutic modalities — small molecules still dominate volume, but RNA therapeutics, PROTACs, CAR-NK cells, and radiopharmaceuticals are growing fast 📍 Molecular targets — 2,000+ emerging topics, including target classes (TRP channels, SWI/SNF complex, C-type lectin receptors) that a decade ago had limited drug development path 📍 Disease areas — 1,700+ emerging topics, with fibrotic and genetic diseases outpacing oncology We visualized all of this in 26 CAS TrendScape maps. Join Janet Sasso, Qiongqiong Angela Zhou, and I as we presenting our findings live in an ACS Webinar on the 15th of July! Register: https://lnkd.in/gNr4FnzT Would be glad to see colleagues from drug discovery, medicinal chemistry, pharmacology, and R&D strategy there. #DrugDiscovery #PharmaceuticalPatents #CAS #ACSWebinar #RNATherapeutics #Oncology #MedicinalChemistry

Drug discovery needs better prediction, not simply more experiments. By combining biochips, organoids, multi-omics, and computational biology, researchers can build human-relevant platforms that improve translational confidence before clinical trials. The future of pharmaceutical innovation will depend on predictive biological systems designed to identify successful therapies earlier, faster, and with greater precision.

I am delighted to share that our research paper has been successfully published in the International Journal of Drug Delivery Technology (IJDDT). 📝 Title: Elucidation of Dioscorea alata Peel as a Multi-Target Neuroprotective Agent Against Alzheimer's Disease Using Network Pharmacology, Molecular Docking, and ADMET Analysis 🔬 Research Highlights: • Investigated the neuroprotective potential of Dioscorea alata peel phytoconstituents against Alzheimer's disease. • Applied Network Pharmacology, Molecular Docking, and ADMET Analysis for comprehensive in-silico evaluation. • Identified Apigenin and Quercetin as promising lead compounds targeting key Alzheimer's-related proteins. • Demonstrated potential modulation of the PI3K–Akt, MAPK, and apoptosis signaling pathways. 📚 Journal: International Journal of Drug Delivery Technology (IJDDT) 📅 Published: May 2026 I sincerely thank my guide Dr. Omprakash Bhusnure, co-authors and Channabasweshwar Pharmacy College for their continuous support and encouragement throughout this research journey. Looking forward to contributing further to pharmaceutical research and drug discovery. #ResearchPublication #PharmaceuticalResearch #AlzheimersDisease #NetworkPharmacology #MolecularDocking #ADMET #DrugDiscovery #Neuroprotection #MPharm #ResearchScholar #IJDDT #Pharmacy #LifeSciences

Nine weeks of learning, critical thinking, and scientific discovery. Scientific Reflection on Selected Drugs in Nervous System and Musculoskeletal Pharmacology brings together insights from the past nine weeks of our course, with a focused scientific analysis of ketamine and Baclofen. The reflection explores their mechanisms of action, clinical applications, adverse effects, therapeutic limitations, unmet clinical needs, and emerging opportunities for pharmaceutical innovation.. My sincere appreciation to Prof. Ermias M. Terefe, PhD for fostering a learning environment that challenged us to think critically, connect science with patient care, and explore the future of pharmacology. I invite you to explore the reflection and share your perspectives on the future of drug discovery and innovation. #Pharmacology #DrugInnovation #PharmacyStudent #MusculoskeletalHealth #Research #USIUAfrica #FutureOfMedicine